Results 201 to 210 of about 29,580 (292)

A case displaying the importance of JAK1 and JAK2 gene transcription in antifungal defense against coccidioidomycosis. [PDF]

Front Med (Lausanne)
Priessnitz JK, Colore T, Nicolasora N.
europepmc   +1 more source

Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib [PDF]

, 2016
Brett King, Alfred Ian Lee, Jaehyuk Choi
openalex   +1 more source

Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase

Clinical and Translational Science, Volume 18, Issue 12, December 2025.
ABSTRACT Janus kinase inhibitors (JAKIs) are immunomodulatory drugs used for autoimmune and inflammatory conditions. Their potential impact on pregnancy and fetal development remains a concern due to placental transfer and potential disruption of cytokine and growth factor signaling, with limited human data.
Nazanin Abolhassani, Roberta Noseda, Kim Dao, François R. Girardin, Francesca Bedussi, Alessandro Ceschi, Alice Panchaud, Ursula Winterfeld   +7 more
wiley   +1 more source

LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis. [PDF]

Front Immunol
Fan H, Sun R, Ma Q, Li X, Liu J, Zhang M, Xu C, Zhang D, Ma W.   +8 more
europepmc   +1 more source

A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT [PDF]

Zachariah DeFilipp, Haesook T. Kim, Guang‐Shing Cheng, Betty K. Hamilton, Saurabh Chhabra, Mehdi Hamadani, Karamjeet Sandhu, Lia Perez, Catherine J. Lee, T. Brennan, Cassandra Garrelts, Bergin M Brown, Kathleen Gallagher, Richard Newcomb, Areej El‐Jawahri, Yi‐Bin Chen   +15 more
openalex   +1 more source

Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo. [PDF]

Dermatol Ther (Heidelb)
Rosmarin D, Pandya AG, Passeron T, Forman SB, Zdybski J, Amster M, Feser C, Papp KA, Nuara A, Kornacki D, Wei S, Ren H, Harris JE, Ezzedine K.   +13 more
europepmc   +1 more source

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review. [PDF]

Int J Mol Sci
Böll SL, Seyed Jafari SM, Conrad C, Schlapbach C.   +3 more
europepmc   +1 more source

Table S3 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

Joe‐Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Léonard-Louis, Stéphane Éderhy, Alban Redheuil, Samia Boussouar, Lee S. Nguyen, Adrien Procureur, Frederic Stein, Charlotte Fenioux, Perrine Devos, Paul Gougis, Martin Dres, Alexandre Demoule, Dimitri Psimaras, Timothée Lenglet, Thierry Maisonobe, Marc Pineton de Chambrun, Guillaume Hékimian, Christian Straus, Jésus González-Bermejo, David Klatzmann, A. Rigolet, Perrine Guillaume-Jugnot, Nicolas Champtiaux, Olivier Benvéniste, Nicolas Weiss, Samir Saheb, Philippe Rouvier, Isabelle Plu, Estelle Gandjbakhch, Mathieu Kerneïs, Nadjib Hammoudi, Noël Zahr, Claudia Llontop, Capucine Morélot‐Panzini, Lorenz Lehmann, Juan Qin, Javid J. Moslehi, Michèlle Rosenzwajg, Thomas Similowski, Yves Allenbach   +42 more
openalex   +1 more source

Fatal encephalopathy with wild‐type JC virus and ruxolitinib therapy

, 2019
Lauren Reoma, Christopher Trindade, Maria Chiara Monaco, Jamie Solis, Marta García‐Montojo, Phuong Thi Vu, Kory R. Johnson, Erin Beck, Govind Nair, Omar Khan, Marta Quezado, Stephen M. Hewitt, Daniel S. Reich, Richard Childs, Avindra Nath   +14 more
openalex   +2 more sources

Regulatory T Cell Dysregulation in Vitiligo: A Meta‐Analysis and Systematic Review of Immune Mechanisms and Therapeutic Perspectives

International Journal of Dermatology, Volume 64, Issue 12, Page 2247-2256, December 2025.
Schematic representation of the methodology, key findings and implications in the context of immune mechanisms and treatment perspectives for vitiligo from the meta‐analysis and systematic review. ABSTRACT Vitiligo is an autoimmune disorder marked by the progressive loss of skin melanocytes, increasingly linked to immune dysregulation as a key driver ...
Gabriela Lerner, Maria Nikolaou, Corinne Stoffel, Eloi Schmauch, Thomas Kündig, Thierry Passeron, Julien Seneschal, Nanja van Geel, Ulrike Held, Antonios G. A. Kolios   +9 more
wiley   +1 more source